Compare Crispr Therapeutics AG (CRSP) vs Ford Motor Company (F) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Ford Motor Company — how do they compare? Crispr Therapeutics AG trades at $50.72 (market cap $4.97B), while Ford Motor Company trades at $14.26 (market cap $55.55B). The key difference: Ford Motor Company is far larger — about 11.2× Crispr Therapeutics AG's market cap, and Ford Motor Company pays a 4.3% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | F | |
|---|---|---|
Market Cap | $4.97B | $55.55B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $17.44 |
52-Week Low | $44.34 | $10.82 |
Enterprise Value | $3.32B | $184.57B |
Dividend Yield | — | 4.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Ford (F) trades at $13.87, down 0.9% with mixed technical signals showing bullish moving averages but neutral oscillators. The company reported a net loss of $8.18 billion in 2025 despite $187.27 billion revenue, with profitability metrics negative. Recent developments include a labor deal with Unifor, J.D. Power quality recognition, and plans for a $30,000 EV truck in 2027. Analyst consensus is mixed with 35% buy ratings and a $15.00 price target.
Ford faces execution risks in EV transition amid competitive pressures, though valuation appears reasonable with P/E of 11.84 and P/S of 0.29. The stock offers value potential if management can stabilize profitability, but investors should monitor EV execution and margin recovery given current negative ROE of -14.87% and ongoing operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Ford Motor Company
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →
